MedTrace Logo

Ultra-high-field Brain MRI in Multiple Sclerosis

NCT05718947 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2024-09-19

No results posted yet for this study

Summary

The MRI scan is one of the most important tools for diagnosing multiple sclerosis (MS) and for monitoring disease progression and medication effects. Increasingly strong MRI magnets (higher field strength) enable us to see abnormalities in the brain in greater detail. On the other hand, it poses challenges because these higher field strength MRIs are more sensitive to disturbances, for example due to motion, including physiological motion such as breathing and swallowing. In current practice, field strengths of up to 3 Tesla are common. The aim of this study is to compare scanning at field strengths of 3 Tesla in 10 MS patients at two different moments (baseline and 6 months) with scanning at field strengths that are higher, namely 7 and 9.4 Tesla, in order to identify the advantages and disadvantages. With the further development of this technique, the investigators may be able to make a better diagnosis in the future and detect subtle changes in the course of the disease more quickly in order to optimize treatments.

Conditions

Interventions

DIAGNOSTIC_TEST

Brain MRI (3T, 7T, 9.4T)

All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2\*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.

Sponsors & Collaborators

  • Scannexus

    collaborator UNKNOWN

  • Zuyderland Medisch Centrum

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-12
Primary Completion
2024-06-17
Completion
2024-06-17

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05718947 on ClinicalTrials.gov